244 related articles for article (PubMed ID: 19663721)
1. Ketorolac tromethamine formulations: an overview.
Sinha VR; Kumar RV; Singh G
Expert Opin Drug Deliv; 2009 Sep; 6(9):961-75. PubMed ID: 19663721
[TBL] [Abstract][Full Text] [Related]
2. Nasal formulations of ketorolac tromethamine: technological evaluation--bioavailability and tolerability in rabbits.
Santus G; Rivolta R; Bottoni G; Testa B; Canali S; Peano S
Farmaco; 1993 Dec; 48(12):1709-23. PubMed ID: 8135994
[TBL] [Abstract][Full Text] [Related]
3. Ketorolac tromethamine transdermal gel: development, in vitro and in vivo evaluation.
Dubey R; Bommagani M; Venkateswarlu V; Mullangi R; Karnati HR; Thammera RK; Menon VC
J Pain Palliat Care Pharmacother; 2009; 23(1):26-34. PubMed ID: 19296352
[TBL] [Abstract][Full Text] [Related]
4. Peripheral prostanoid levels and nonsteroidal anti-inflammatory drug analgesia: replicate clinical trials in a tissue injury model.
Gordon SM; Brahim JS; Rowan J; Kent A; Dionne RA
Clin Pharmacol Ther; 2002 Aug; 72(2):175-83. PubMed ID: 12189364
[TBL] [Abstract][Full Text] [Related]
5. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt.
Rooks WH; Maloney PJ; Shott LD; Schuler ME; Sevelius H; Strosberg AM; Tanenbaum L; Tomolonis AJ; Wallach MB; Waterbury D
Drugs Exp Clin Res; 1985; 11(8):479-92. PubMed ID: 3879752
[TBL] [Abstract][Full Text] [Related]
6. Comparative bioavailability of ketorolac tromethamine after intramuscular and sublingual administration.
Pérez-Urizar J; Aguilar-Cota ME; Herrera JE; Flores-Murrieta FJ
Proc West Pharmacol Soc; 2002; 45():6-7. PubMed ID: 12434509
[No Abstract] [Full Text] [Related]
7. Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose.
Nagilla R; Deshmukh DD; Copedge KJ; Miller S; Martin B; Bell EC; Duran SH; Ravis WR
J Vet Pharmacol Ther; 2009 Feb; 32(1):49-55. PubMed ID: 19161455
[TBL] [Abstract][Full Text] [Related]
8. Eudragit matrices for sustained release of ketorolac tromethamine: formulation and kinetics of release.
Ruckmani K; Muneera MS; Vijaya R
Boll Chim Farm; 2000; 139(5):205-8. PubMed ID: 11213438
[TBL] [Abstract][Full Text] [Related]
9. A novel formulation of ketorolac tromethamine for intranasal administration: preclinical safety evaluation.
Boyer KC; McDonald P; Zoetis T
Int J Toxicol; 2010; 29(5):467-78. PubMed ID: 20884857
[TBL] [Abstract][Full Text] [Related]
10. Ketorolac trometamol topical formulations: release behaviour, physical characterization, skin permeation, efficacy and gastric safety.
El-Setouhy DA; El-Ashmony SM
J Pharm Pharmacol; 2010 Jan; 62(1):25-34. PubMed ID: 20722996
[TBL] [Abstract][Full Text] [Related]
11. Corneal ulceration and perforation with ketorolac tromethamine.
Lee WB; Himmel K
Cornea; 2006 Dec; 25(10):1268. PubMed ID: 17172920
[No Abstract] [Full Text] [Related]
12. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.
Schoenberger SD; Kim SJ; Sheng J; Calcutt MW
JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary and nasal deposition of ketorolac tromethamine solution (SPRIX) following intranasal administration.
Bacon R; Newman S; Rankin L; Pitcairn G; Whiting R
Int J Pharm; 2012 Jul; 431(1-2):39-44. PubMed ID: 22525081
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients.
Drover DR; Hammer GB; Anderson BJ
Anesth Analg; 2012 Jun; 114(6):1270-6. PubMed ID: 22467894
[TBL] [Abstract][Full Text] [Related]
15. Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies.
M A Fathalla Z; Vangala A; Longman M; Khaled KA; Hussein AK; El-Garhy OH; Alany RG
Eur J Pharm Biopharm; 2017 May; 114():119-134. PubMed ID: 28126392
[TBL] [Abstract][Full Text] [Related]
16. Nasal delivery of analgesic ketorolac tromethamine thermo- and ion-sensitive in situ hydrogels.
Li X; Du L; Chen X; Ge P; Wang Y; Fu Y; Sun H; Jiang Q; Jin Y
Int J Pharm; 2015 Jul; 489(1-2):252-60. PubMed ID: 25957699
[TBL] [Abstract][Full Text] [Related]
17. Plasma prostaglandin E2 concentrations after single dose administration of ketorolac tromethamine (Toradol) in dogs.
Pasloske K; Burger J; Conlon P
Can J Vet Res; 1998 Jul; 62(3):237-40. PubMed ID: 9684056
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits.
Wang M; Liu W; Lu Q; Zeng H; Liu S; Yue Y; Cheng H; Liu Y; Xue M
Retina; 2012; 32(10):2158-64. PubMed ID: 23099451
[TBL] [Abstract][Full Text] [Related]
19. Preparation and in vitro evaluation of controlled release hydrophilic matrix tablets of ketorolac tromethamine using factorial design.
Genç L; Jalvand E
Drug Dev Ind Pharm; 2008 Aug; 34(8):903-10. PubMed ID: 18686094
[TBL] [Abstract][Full Text] [Related]
20. The antinociceptive and anti-inflammatory effects of a long-acting depot formulated ketorolac in rats.
Tzeng JI; Chu CC; Feng PH; Hou CH; Shieh JP; Ho ST; Wang JJ
Acta Anaesthesiol Taiwan; 2005 Mar; 43(1):17-22. PubMed ID: 15869000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
